Zhejiang Jingxin Pharmaceutical: Summary table of non-operating funds utilization and other related funds flow for the first half of the year.
Zhejiang Jingxin Pharmaceutical: Announcement regarding increase in entrusted wealth management limit of idle proprietary funds.
Zhejiang Jingxin Pharmaceutical: Financial Report for the first half of 2024.
Zhejiang Jingxin Pharmaceutical: Announcement Regarding Enrofloxacin Active Pharmaceutical Ingredient, a wholly-owned subsidiary, obtaining the European CEP certificate.
Jingxin Pharmaceutical: Announcement of Resolutions of the 2023 Annual General Meeting of Shareholders
Jingxin Pharmaceutical: Legal Opinion of Shanghai AllBright Law Firm on the 2023 Annual General Meeting of Shareholders of Zhejiang Jingxin Pharmaceutical Co., Ltd.
Jingxin Pharmaceutical: Announcement on providing guarantees to wholly-owned subsidiaries
Jingxin Pharmaceutical: Working System for Special Meetings of Independent Directors
Jingxin Pharmaceutical: Announcement on Launching Foreign Exchange Hedging Business
Jingxin Pharmaceutical: Rules of Procedure for the Nomination Committee of the Board of Directors (revised in March 2024)
Jingxin Pharmaceutical: Announcement on Shaxi Pharmaceutical\'s unfulfilled performance commitments and related performance compensation
Jingxin Pharmaceutical: Internal Control Self-Assessment Report
Jingxin Pharmaceutical: Rules of Procedure for Audit Committee of the Board of Directors (revised in March 2024)
Jingxin Pharmaceutical: Report of the Audit Committee of the Board of Directors on the evaluation of the performance of accounting firms in 2023 and the performance of supervisory duties
Jingxin Pharmaceutical: Notice on Amending the “Articles of Association”
Jingxin Pharmaceutical: Articles of Association (revised in March 2024)
Jingxin Pharmaceutical: Notice of Annual General Meeting of Shareholders
Jingxin Pharmaceutical: Announcement on Using Idle Own Funds for Outsourced Financial Management
Jingxin Pharmaceutical: Announcement on the Resignation of Vice President
Jingxin Pharmaceutical: Announcement on approval for marketing of didacinib capsules
No Data
No Data